NASDAQ
CERS

Cerus Corporation

Medical Devices
Healthcare

Prices are adjusted according to historical splits.

Cerus Corporation Stock Price

Vitals

Today's Low:
$1.675
Today's High:
$1.79
Open Price:
$1.69
52W Low:
$1.76
52W High:
$5.95
Prev. Close:
$1.68
Volume:
914509

Company Statistics

Market Cap.:
$408.05 million
Book Value:
0.325
Revenue TTM:
$155.58 million
Operating Margin TTM:
-24.67%
Gross Profit TTM:
$87.09 million
Profit Margin:
-29.64%
Return on Assets TTM:
-11.12%
Return on Equity TTM:
-65.99%

Company Profile

Cerus Corporation had its IPO on 1997-01-30 under the ticker symbol CERS.

The company operates in the Healthcare sector and Medical Devices industry. Cerus Corporation has a staff strength of 665 employees.

Stock update

Shares of Cerus Corporation opened at $1.69 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $1.68 - $1.79, and closed at $1.74.

This is a +3.57% increase from the previous day's closing price.

A total volume of 914,509 shares were traded at the close of the day’s session.

In the last one week, shares of Cerus Corporation have slipped by -9.38%.

Cerus Corporation's Key Ratios

Cerus Corporation has a market cap of $408.05 million, indicating a price to book ratio of 9.5602 and a price to sales ratio of 4.7423.

In the last 12-months Cerus Corporation’s revenue was $155.58 million with a gross profit of $87.09 million and an EBITDA of $-35625000. The EBITDA ratio measures Cerus Corporation's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Cerus Corporation’s operating margin was -24.67% while its return on assets stood at -11.12% with a return of equity of -65.99%.

In Q1, Cerus Corporation’s quarterly earnings growth was a positive 0% while revenue growth was a negative 17.3%.

Cerus Corporation’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG
0

Its diluted EPS in the last 12-months stands at $-0.27 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Cerus Corporation’s profitability.

Cerus Corporation stock is trading at a EV to sales ratio of 4.324 and a EV to EBITDA ratio of -23.2088. Its price to sales ratio in the trailing 12-months stood at 4.7423.

Cerus Corporation stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$209.34 million
Total Liabilities
$77.57 million
Operating Cash Flow
$-1646000.00
Capital Expenditure
$1.52 million
Dividend Payout Ratio
0%

Cerus Corporation ended 2024 with $209.34 million in total assets and $0 in total liabilities. Its intangible assets were valued at $209.34 million while shareholder equity stood at $58.63 million.

Cerus Corporation ended 2024 with $0 in deferred long-term liabilities, $77.57 million in other current liabilities, 180000.00 in common stock, $-1022740000.00 in retained earnings and $1.32 million in goodwill. Its cash balance stood at $27.60 million and cash and short-term investments were $94.68 million. The company’s total short-term debt was $20,157,000 while long-term debt stood at $54.83 million.

Cerus Corporation’s total current assets stands at $162.22 million while long-term investments were $0 and short-term investments were $67.08 million. Its net receivables were $25.24 million compared to accounts payable of $36.44 million and inventory worth $36.61 million.

In 2024, Cerus Corporation's operating cash flow was $-1646000.00 while its capital expenditure stood at $1.52 million.

Comparatively, Cerus Corporation paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$1.74
52-Week High
$5.95
52-Week Low
$1.76
Analyst Target Price
$7.63

Cerus Corporation stock is currently trading at $1.74 per share. It touched a 52-week high of $5.95 and a 52-week low of $5.95. Analysts tracking the stock have a 12-month average target price of $7.63.

Its 50-day moving average was $2.21 and 200-day moving average was $2.73 The short ratio stood at 6.62 indicating a short percent outstanding of 0%.

Around 313.9% of the company’s stock are held by insiders while 8272.9% are held by institutions.

Frequently Asked Questions About Cerus Corporation

The stock symbol (also called stock or share ticker) of Cerus Corporation is CERS

The IPO of Cerus Corporation took place on 1997-01-30

Similar Industry Stocks (Medical Devices)

Last Price
Chg
Chg%
$429.25
-17
-3.81%
HyreCar Inc (HYRE)
$0.02
0
0%
$27.46
-0.24
-0.87%
$5.94
0.22
+3.85%
$2.84
-0.03
-0.89%
$3.23
0.08
+2.54%
$272.3
-4.9
-1.77%
$36.52
2.46
+7.22%
$33.1
-0.11
-0.33%
$16.3
-0.33
-1.98%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.

Address

1220 Concord Avenue, Concord, CA, United States, 94520